CR20200312A - Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 - Google Patents
Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1Info
- Publication number
- CR20200312A CR20200312A CR20200312A CR20200312A CR20200312A CR 20200312 A CR20200312 A CR 20200312A CR 20200312 A CR20200312 A CR 20200312A CR 20200312 A CR20200312 A CR 20200312A CR 20200312 A CR20200312 A CR 20200312A
- Authority
- CR
- Costa Rica
- Prior art keywords
- pyridopyrimidinones
- sos
- benzylamine
- derivatives
- substituted
- Prior art date
Links
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical group NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 title 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 101100404726 Arabidopsis thaliana NHX7 gene Proteins 0.000 abstract 1
- 102000057028 SOS1 Human genes 0.000 abstract 1
- 108700022176 SOS1 Proteins 0.000 abstract 1
- 101100197320 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) RPL35A gene Proteins 0.000 abstract 1
- 101150100839 Sos1 gene Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
<p>La presente invención abarca compuestos de fórmula <strong>(I) </strong>donde los grupos <strong>R</strong><strong>1 </strong>a <strong>R</strong><strong>4</strong>, <strong>A </strong>y <strong>p </strong>tienen los significados dados en las reivindicaciones y la memoria descriptiva, su uso como inhibidores de SOS1, composiciones farmacéuticas 5 que contienen compuestos de esta clase y su uso como medicamentos/usos médicos, especialmente como agentes para el tratamiento y/o la prevención de enfermedades oncológicas.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17209865 | 2017-12-21 | ||
| PCT/EP2018/086197 WO2019122129A1 (en) | 2017-12-21 | 2018-12-20 | Novel benzylamino substituted pyridopyrimidinones and derivatives as sos1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200312A true CR20200312A (es) | 2020-09-11 |
Family
ID=60781991
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210307A CR20210307A (es) | 2017-12-21 | 2018-12-20 | NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312) |
| CR20200312A CR20200312A (es) | 2017-12-21 | 2018-12-20 | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210307A CR20210307A (es) | 2017-12-21 | 2018-12-20 | NUEVAS PIRIDOPIRIMIDINONAS SUSTITUIDAS CON BENCILAMINO Y DERIVADOS COMO INHIBIDORES DE SOS1 (Divisional 2020-312) |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10829487B2 (es) |
| EP (2) | EP4219493A1 (es) |
| JP (1) | JP7189956B2 (es) |
| KR (1) | KR102746913B1 (es) |
| CN (1) | CN111372932B (es) |
| AR (1) | AR114164A1 (es) |
| AU (1) | AU2018390927B2 (es) |
| BR (1) | BR112020010123A2 (es) |
| CA (1) | CA3085835A1 (es) |
| CL (2) | CL2020001501A1 (es) |
| CO (1) | CO2020007218A2 (es) |
| CR (2) | CR20210307A (es) |
| DK (1) | DK3728254T3 (es) |
| EA (1) | EA202091491A1 (es) |
| EC (1) | ECSP20040257A (es) |
| ES (1) | ES2944306T3 (es) |
| FI (1) | FI3728254T3 (es) |
| HR (1) | HRP20230400T1 (es) |
| HU (1) | HUE062076T2 (es) |
| IL (1) | IL275379B2 (es) |
| JO (1) | JOP20200154B1 (es) |
| LT (1) | LT3728254T (es) |
| MA (1) | MA51290A (es) |
| MX (1) | MX2020006438A (es) |
| MY (1) | MY208632A (es) |
| PE (1) | PE20210163A1 (es) |
| PH (1) | PH12020550786A1 (es) |
| PL (1) | PL3728254T3 (es) |
| PT (1) | PT3728254T (es) |
| RS (1) | RS64167B1 (es) |
| SA (1) | SA520412278B1 (es) |
| SG (1) | SG11202005881YA (es) |
| SI (1) | SI3728254T1 (es) |
| TW (2) | TWI870922B (es) |
| UA (1) | UA126173C2 (es) |
| WO (1) | WO2019122129A1 (es) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL295978B2 (en) | 2017-10-18 | 2024-01-01 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
| TWI870922B (zh) * | 2017-12-21 | 2025-01-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN114375202A (zh) | 2019-06-19 | 2022-04-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
| WO2021074227A1 (en) * | 2019-10-15 | 2021-04-22 | Bayer Aktiengesellschaft | 2-methyl-aza-quinazolines |
| BR112022008858A2 (pt) * | 2019-11-08 | 2022-09-06 | Revolution Medicines Inc | Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer |
| WO2021105960A1 (en) * | 2019-11-29 | 2021-06-03 | Lupin Limited | Substituted tricyclic compounds |
| EP4076418A4 (en) * | 2019-12-20 | 2024-01-24 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| CN113045565A (zh) * | 2019-12-27 | 2021-06-29 | 微境生物医药科技(上海)有限公司 | 新型K-Ras G12C抑制剂 |
| WO2021130731A1 (en) * | 2019-12-27 | 2021-07-01 | Lupin Limited | Substituted tricyclic compounds |
| WO2021173524A1 (en) * | 2020-02-24 | 2021-09-02 | Mirati Therapeutics, Inc. | Sos1 inhibitors |
| CN115244058A (zh) * | 2020-04-08 | 2022-10-25 | 江苏恒瑞医药股份有限公司 | 嘧啶并二环类衍生物、其制备方法及其在医药上的应用 |
| BR112022023462A2 (pt) | 2020-06-02 | 2022-12-20 | Boehringer Ingelheim Int | 2-amino-3-ciano tiofenos anulados e derivados para o tratamento de câncer |
| CN115605479B (zh) * | 2020-06-11 | 2024-05-14 | 江苏恒瑞医药股份有限公司 | 吡啶酮并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN113801114B (zh) * | 2020-06-11 | 2022-11-18 | 江苏恒瑞医药股份有限公司 | 稠合二环杂芳基类衍生物、其制备方法及其在医药上的应用 |
| CN115942936A (zh) * | 2020-06-24 | 2023-04-07 | 勃林格殷格翰国际有限公司 | 包含sos1抑制剂和kras g12c抑制剂的抗癌组合疗法 |
| CN113912608B (zh) * | 2020-07-10 | 2023-07-14 | 江苏恒瑞医药股份有限公司 | 嘧啶并嘧啶酮类衍生物、其制备方法及其在医药上的应用 |
| WO2022017519A1 (zh) * | 2020-07-24 | 2022-01-27 | 南京明德新药研发有限公司 | 喹唑啉类化合物 |
| TWI793704B (zh) * | 2020-08-06 | 2023-02-21 | 大陸商北京泰德製藥股份有限公司 | Sos1抑制劑、包含其的藥物組合物及其用途 |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| CR20230165A (es) | 2020-09-15 | 2023-06-02 | Revolution Medicines Inc | Derivados indólicos como inhibidores de ras en el tratamiento del cáncer |
| WO2022061348A1 (en) | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| US20230357239A1 (en) | 2020-09-18 | 2023-11-09 | Bayer Aktiengesellschaft | Pyrido[2,3-d]pyrimidin-4-amines as sos1 inhibitors |
| KR20230093300A (ko) | 2020-10-20 | 2023-06-27 | 쑤저우 젤겐 바이오파마슈티칼즈 컴퍼니 리미티드 | 치환된 벤조 또는 피리도피리미딘 아민계 억제제 및 이의 제조 방법과 응용 |
| WO2022105921A1 (zh) * | 2020-11-21 | 2022-05-27 | 上海凌达生物医药有限公司 | 一类嘧啶并杂环类化合物、制备方法和用途 |
| CN117396472A (zh) * | 2020-12-22 | 2024-01-12 | 上海齐鲁锐格医药研发有限公司 | Sos1抑制剂及其用途 |
| US20240254117A1 (en) * | 2020-12-27 | 2024-08-01 | Shanghai Ringene Biopharma Co., Ltd. | Pyrimido-heterocyclic compounds, and preparation method therefor and use thereof |
| CN114685488A (zh) * | 2020-12-31 | 2022-07-01 | 南京圣和药业股份有限公司 | 作为sos1抑制剂的化合物及其应用 |
| CN116723843A (zh) * | 2021-01-19 | 2023-09-08 | 鲁宾有限公司 | 用于治疗和/或预防癌症的sos1抑制剂的药物组合 |
| WO2022160931A1 (zh) * | 2021-01-28 | 2022-08-04 | 浙江海正药业股份有限公司 | 吡啶并嘧啶类衍生物及其制备方法和用途 |
| CN114436976B (zh) * | 2021-01-29 | 2023-07-11 | 石药集团中奇制药技术（石家庄）有限公司 | 一种新型喹唑啉类衍生物及其制备和应用 |
| WO2022161461A1 (zh) * | 2021-01-29 | 2022-08-04 | 江苏先声药业有限公司 | Sos1抑制剂及其制备方法和应用 |
| CN114835719A (zh) * | 2021-02-01 | 2022-08-02 | 苏州泽璟生物制药股份有限公司 | 取代双环并芳杂环胺类抑制剂及其制备方法和应用 |
| CN114835703A (zh) * | 2021-02-02 | 2022-08-02 | 苏州泽璟生物制药股份有限公司 | 取代嘧啶并吡啶酮类抑制剂及其制备方法和应用 |
| WO2022166974A1 (zh) | 2021-02-08 | 2022-08-11 | 武汉人福创新药物研发中心有限公司 | 吡啶并嘧啶酮类衍生物及其制备方法和用途 |
| CN116669738A (zh) * | 2021-02-09 | 2023-08-29 | 苏州阿尔脉生物科技有限公司 | 一种作为sos1抑制剂的嘧啶并吡啶酮类衍生物、其制备方法及用途 |
| CN114907284B (zh) * | 2021-02-10 | 2023-11-03 | 石药集团中奇制药技术（石家庄）有限公司 | 一种具有抗肿瘤活性的化合物及其用途 |
| CN113200981A (zh) * | 2021-02-10 | 2021-08-03 | 杭州英创医药科技有限公司 | 作为sos1抑制剂的杂环化合物 |
| WO2022187411A1 (en) | 2021-03-02 | 2022-09-09 | Kumquat Biosciences Inc. | Heterocycles and uses thereof |
| CN117062818A (zh) * | 2021-03-05 | 2023-11-14 | 南京再明医药有限公司 | 新型sos1抑制剂及其制备方法和应用 |
| JP2024511507A (ja) * | 2021-03-26 | 2024-03-13 | メッドシャイン ディスカバリー インコーポレイテッド | ６－カルバメート置換複素芳香環誘導体 |
| WO2022212546A1 (en) * | 2021-03-31 | 2022-10-06 | Acerand Therapeutics (Usa) Limited | Pyridopyrimidinone compounds |
| WO2022207673A1 (en) | 2021-03-31 | 2022-10-06 | Sevenless Therapeutics Limited | Sos1 inhibitors and ras inhibitors for use in the treatment of pain |
| GB202104609D0 (en) | 2021-03-31 | 2021-05-12 | Sevenless Therapeutics Ltd | New Treatments for Pain |
| CN117979966A (zh) * | 2021-04-09 | 2024-05-03 | 锐新医药公司 | 使用sos1抑制剂和ras抑制剂治疗癌症 |
| WO2022214594A1 (en) | 2021-04-09 | 2022-10-13 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
| US12037346B2 (en) | 2021-04-13 | 2024-07-16 | Nuvalent, Inc. | Amino-substituted heteroaryls for treating cancers with EGFR mutations |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| TWI807787B (zh) * | 2021-04-19 | 2023-07-01 | 大陸商昆藥集團股份有限公司 | 苯並嘧啶三環衍生物及製備方法和應用 |
| WO2022223033A1 (zh) | 2021-04-23 | 2022-10-27 | 上海领泰生物医药科技有限公司 | Sos1降解剂及其制备方法和应用 |
| KR20240013792A (ko) * | 2021-05-27 | 2024-01-30 | 슈뢰딩거, 인크. | 헤테로시클릭 화합물 및 사용 방법 |
| CA3227706A1 (en) | 2021-07-27 | 2023-02-02 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| EP4375284A1 (en) * | 2021-08-03 | 2024-05-29 | Evopoint Biosciences Co., Ltd. | Fused ring compound, pharmaceutical composition, and application thereof |
| WO2023020347A1 (zh) * | 2021-08-16 | 2023-02-23 | 华润医药研究院（深圳）有限公司 | 嘧啶并吡啶类化合物及其制备方法和医药用途 |
| JP2024534804A (ja) * | 2021-08-17 | 2024-09-26 | カナプ セラピューティクス インコーポレイテッド | Ｓｏｓ１阻害剤及びその使用 |
| CN117730080A (zh) * | 2021-08-30 | 2024-03-19 | 浙江海正药业股份有限公司 | 吡啶并嘧啶酮类衍生物及其制备方法和用途 |
| CN117836278A (zh) * | 2021-09-02 | 2024-04-05 | 上海海和药物研究开发股份有限公司 | 一种sos1抑制剂、其制备方法及用途 |
| CN117986265A (zh) * | 2021-09-14 | 2024-05-07 | 北京福元医药股份有限公司 | 苄氨基取代的嘧啶并吡喃酮衍生物及其组合物、制剂和用途 |
| CN117957226A (zh) | 2021-09-17 | 2024-04-30 | 南京再明医药有限公司 | 作为sos1抑制剂的杂环化合物及其用途 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN115536660B (zh) * | 2021-11-04 | 2025-09-02 | 北京福元医药股份有限公司 | 苄氨基取代的杂多环化合物及其组合物、制剂和用途 |
| CN115724844B (zh) * | 2021-11-22 | 2024-10-18 | 石药集团中奇制药技术（石家庄）有限公司 | 一种具有抗肿瘤活性的杂环化合物及其用途 |
| JP2024543976A (ja) | 2021-12-01 | 2024-11-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体 |
| US20250129096A1 (en) | 2021-12-01 | 2025-04-24 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN119841847A (zh) | 2021-12-01 | 2025-04-18 | 勃林格殷格翰国际有限公司 | 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物 |
| US20250129095A1 (en) | 2021-12-01 | 2025-04-24 | Boehringer Ingelheim Int'l GmbH Corp. | Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer |
| CN118591540A (zh) | 2021-12-01 | 2024-09-03 | 勃林格殷格翰国际有限公司 | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 |
| CA3240780A1 (en) * | 2021-12-17 | 2023-06-22 | Zhenyu Wang | Heterocyclic compound having anti-tumor activity and use thereof |
| JP2025500878A (ja) | 2021-12-17 | 2025-01-15 | ジェンザイム・コーポレーション | Ｓｈｐ２阻害剤としてのピラゾロピラジン化合物 |
| WO2023125737A1 (en) * | 2021-12-29 | 2023-07-06 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds and use thereof |
| EP4463454A1 (en) | 2022-01-14 | 2024-11-20 | Jazz Pharmaceuticals Ireland Limited | Novel amine-substituted phthalazines and derivatives as sos1 inhibitors |
| CN118696042A (zh) * | 2022-01-21 | 2024-09-24 | 南京明德新药研发有限公司 | 含烯丙基的甲基吡啶并嘧啶化合物的晶型 |
| WO2023143147A1 (zh) * | 2022-01-28 | 2023-08-03 | 上海优理惠生医药有限公司 | 一种哒嗪并吡啶酮类化合物、其药物组合物及应用 |
| TW202342461A (zh) * | 2022-02-04 | 2023-11-01 | 美商薛定諤公司 | 雜環化合物及使用方法 |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN116768858B (zh) * | 2022-03-15 | 2025-09-12 | 杭州中美华东制药有限公司 | 具有kras-sos1抑制或降解活性的嵌合化合物及其用途 |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
| GB202203976D0 (en) | 2022-03-22 | 2022-05-04 | Jazz Pharmaceuticals Ireland Ltd | Tricyclic phthalazines and derivatives as sos1 inhibitors |
| IL316144A (en) | 2022-04-20 | 2024-12-01 | Kumquat Biosciences Inc | Macrocyclic heterocycles and their uses |
| WO2023215257A2 (en) * | 2022-05-03 | 2023-11-09 | Revolution Medicines, Inc. | Sos1 inhibitors and uses thereof |
| WO2023215256A1 (en) * | 2022-05-03 | 2023-11-09 | Revolution Medicines, Inc. | Sos1 inhibitors and uses thereof |
| TW202404581A (zh) | 2022-05-25 | 2024-02-01 | 美商醫肯納腫瘤學公司 | Ｍｅｋ抑制劑及其用途 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024002318A1 (zh) * | 2022-07-01 | 2024-01-04 | 四川汇宇制药股份有限公司 | 哒嗪并吡啶酮衍生物及其用途 |
| WO2024008185A1 (zh) * | 2022-07-07 | 2024-01-11 | 武汉人福创新药物研发中心有限公司 | 包含sos1抑制剂的药物组合物 |
| CN115057847B (zh) * | 2022-07-26 | 2024-01-26 | 山东百启生物医药有限公司 | 一种4,6-二氯-5-(1,3-二氧戊环-2-基)-2-甲基嘧啶的制备方法 |
| CN119451960A (zh) * | 2022-08-05 | 2025-02-14 | 上海艾力斯医药科技股份有限公司 | 一种稠环化合物、其制备方法及其应用 |
| EP4570800A1 (en) | 2022-08-08 | 2025-06-18 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Crystal form of pyridinopyrimidinone compound, acid salt thereof, crystal form of acid salt thereof, and use |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| EP4587439A1 (en) | 2022-09-16 | 2025-07-23 | Bayer Aktiengesellschaft | Sulfone-substituted pyrido[3,4-d]pyrimidine derivatives for the treatment of cancer |
| WO2024074827A1 (en) | 2022-10-05 | 2024-04-11 | Sevenless Therapeutics Limited | New treatments for pain |
| EP4602049A1 (en) | 2022-10-13 | 2025-08-20 | Bayer Aktiengesellschaft | Sos1 inhibitors |
| TW202448871A (zh) * | 2023-02-16 | 2024-12-16 | 南韓商賽勒斯治療有限公司 | 作為sos1抑制劑之唑基吡啶嗒酮醯胺 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| PE20260039A1 (es) | 2023-04-07 | 2026-01-09 | Revolution Medicines Inc | Inhibidores macrociclicos de ras |
| TW202448897A (zh) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑之結晶形式、含有其之組合物及其使用方法 |
| CN121100123A (zh) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Ras抑制剂的结晶形式 |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| TW202500126A (zh) | 2023-05-24 | 2025-01-01 | 美商金橘生物科技公司 | 雜環化合物及其用途 |
| AR132802A1 (es) | 2023-05-30 | 2025-07-30 | Boehringer Ingelheim Int | 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer |
| GB2631397A (en) | 2023-06-28 | 2025-01-08 | Sevenless Therapeutics Ltd | New treatments for pain |
| WO2025007000A1 (en) | 2023-06-30 | 2025-01-02 | Kumquat Biosciences Inc. | Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202515575A (zh) | 2023-09-11 | 2025-04-16 | 美商金橘生物科技公司 | 細胞增殖調節劑及其用途 |
| WO2025064848A1 (en) | 2023-09-21 | 2025-03-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyridine kras inhibitors |
| GB2633813A (en) | 2023-09-21 | 2025-03-26 | Sevenless Therapeutics Ltd | New treatments for pain |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025083426A1 (en) | 2023-10-20 | 2025-04-24 | Sevenless Therapeutics Limited | New treatments for pain |
| WO2025090808A1 (en) | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Combinations of sos-1 inhibitors with osimertinib and/or met inhibitors to treat cancer |
| WO2025090810A1 (en) | 2023-10-25 | 2025-05-01 | Kumquat Biosciences Inc. | Use of sos1 inhibitors and amivantamab to treat cancer |
| TW202542151A (zh) * | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Ｓｏｓ１抑制劑及其用途 |
| WO2025146548A1 (en) | 2024-01-04 | 2025-07-10 | Sevenless Therapeutics Limited | Sos1 inhibitors useful to treat pain and cancer |
| TW202545999A (zh) | 2024-02-06 | 2025-12-01 | 美商金橘生物科技公司 | 雜環綴合物及其用途 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025202022A1 (en) | 2024-03-27 | 2025-10-02 | Bayer Aktiengesellschaft | Anticancer macrocyclic quinazoline-based inhibitors of the ineraction between ras and sos1 |
| WO2025210042A1 (en) | 2024-04-03 | 2025-10-09 | Boehringer Ingelheim International Gmbh | Combination of zongertinib with a sos1 inhibitor for use in the treatment of cancer |
| WO2025230971A1 (en) | 2024-04-30 | 2025-11-06 | Kumquat Biosciences Inc. | Macrocyclic heterocycles as anticancer agents |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5654307A (en) * | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| US6174899B1 (en) | 1998-05-14 | 2001-01-16 | Morton Shulman | Orally administered analgesic composition comprising myfadol |
| EP2139895A1 (en) | 2007-03-23 | 2010-01-06 | F. Hoffmann-Roche AG | Aza-pyridopyrimidinone derivatives |
| TWI377944B (en) | 2007-06-05 | 2012-12-01 | Hanmi Holdings Co Ltd | Novel amide derivative for inhibiting the growth of cancer cells |
| ES2432414T3 (es) | 2008-08-12 | 2013-12-03 | Glaxosmithkline Llc | Compuestos químicos |
| AU2009319051A1 (en) | 2008-11-28 | 2010-06-03 | Novartis Ag | Hsp90 inhibitors for therapeutic treatment |
| AR074726A1 (es) | 2008-12-12 | 2011-02-09 | Boehringer Ingelheim Int | Anticuerpos anti-igf (factor de crecimiento insulinico) |
| ES2658290T3 (es) | 2009-10-29 | 2018-03-09 | Genosco | Inhibidores de cinasa |
| EP2649016B1 (en) | 2010-12-06 | 2020-06-10 | Pall Corporation | Continuous processing methods for biological products |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| UA114906C2 (uk) * | 2012-03-14 | 2017-08-28 | Люпін Лімітед | Гетероциклільні сполуки як інгібітори мек |
| US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| EP2970121B1 (en) | 2013-03-15 | 2017-12-13 | Araxes Pharma LLC | Covalent inhibitors of kras g12c |
| WO2015025326A1 (en) * | 2013-08-19 | 2015-02-26 | Council Of Scientific & Industrial Research | 3-(4-ethynylphenyl) pyridopyrimidinone compounds and process for preparation thereof useful as potential antic ancer agents |
| JO3556B1 (ar) | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| WO2016077793A1 (en) | 2014-11-14 | 2016-05-19 | Children's Hospital Medical Center | Sos1 inhibitors for cancer treatment |
| CN107286180B (zh) * | 2016-04-11 | 2019-07-02 | 上海勋和医药科技有限公司 | 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用 |
| EP3558979B1 (en) | 2016-12-22 | 2021-02-17 | Boehringer Ingelheim International GmbH | Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors |
| US20220235013A1 (en) | 2017-03-21 | 2022-07-28 | Bayer Pharma Aktiengesellschaft | 2-methyl-quinazolines |
| TWI870922B (zh) * | 2017-12-21 | 2025-01-21 | 德商百靈佳殷格翰國際股份有限公司 | 作為sos1抑制劑之新穎芐胺基取代吡啶并嘧啶酮及衍生物 |
| CN114375202A (zh) * | 2019-06-19 | 2022-04-19 | 勃林格殷格翰国际有限公司 | 抗癌组合疗法 |
-
2018
- 2018-12-20 TW TW112125294A patent/TWI870922B/zh active
- 2018-12-20 PH PH1/2020/550786A patent/PH12020550786A1/en unknown
- 2018-12-20 HU HUE18830816A patent/HUE062076T2/hu unknown
- 2018-12-20 EP EP23156525.0A patent/EP4219493A1/en not_active Withdrawn
- 2018-12-20 AR ARP180103772A patent/AR114164A1/es unknown
- 2018-12-20 US US16/226,824 patent/US10829487B2/en active Active
- 2018-12-20 HR HRP20230400TT patent/HRP20230400T1/hr unknown
- 2018-12-20 CR CR20210307A patent/CR20210307A/es unknown
- 2018-12-20 JP JP2020533742A patent/JP7189956B2/ja active Active
- 2018-12-20 SI SI201830909T patent/SI3728254T1/sl unknown
- 2018-12-20 WO PCT/EP2018/086197 patent/WO2019122129A1/en not_active Ceased
- 2018-12-20 CA CA3085835A patent/CA3085835A1/en active Pending
- 2018-12-20 RS RS20230333A patent/RS64167B1/sr unknown
- 2018-12-20 PT PT188308167T patent/PT3728254T/pt unknown
- 2018-12-20 KR KR1020207017298A patent/KR102746913B1/ko active Active
- 2018-12-20 PL PL18830816.7T patent/PL3728254T3/pl unknown
- 2018-12-20 AU AU2018390927A patent/AU2018390927B2/en active Active
- 2018-12-20 BR BR112020010123-0A patent/BR112020010123A2/pt active Search and Examination
- 2018-12-20 EP EP18830816.7A patent/EP3728254B1/en active Active
- 2018-12-20 DK DK18830816.7T patent/DK3728254T3/da active
- 2018-12-20 MX MX2020006438A patent/MX2020006438A/es unknown
- 2018-12-20 MY MYPI2020003204A patent/MY208632A/en unknown
- 2018-12-20 EA EA202091491A patent/EA202091491A1/ru unknown
- 2018-12-20 FI FIEP18830816.7T patent/FI3728254T3/fi active
- 2018-12-20 MA MA051290A patent/MA51290A/fr unknown
- 2018-12-20 UA UAA202004415A patent/UA126173C2/uk unknown
- 2018-12-20 CR CR20200312A patent/CR20200312A/es unknown
- 2018-12-20 LT LTEPPCT/EP2018/086197T patent/LT3728254T/lt unknown
- 2018-12-20 CN CN201880075128.0A patent/CN111372932B/zh active Active
- 2018-12-20 SG SG11202005881YA patent/SG11202005881YA/en unknown
- 2018-12-20 ES ES18830816T patent/ES2944306T3/es active Active
- 2018-12-20 TW TW107146126A patent/TWI810230B/zh active
- 2018-12-20 PE PE2020000811A patent/PE20210163A1/es unknown
-
2020
- 2020-06-05 CL CL2020001501A patent/CL2020001501A1/es unknown
- 2020-06-12 CO CONC2020/0007218A patent/CO2020007218A2/es unknown
- 2020-06-15 IL IL275379A patent/IL275379B2/en unknown
- 2020-06-18 JO JOJO/P/2020/0154A patent/JOP20200154B1/ar active
- 2020-06-19 SA SA520412278A patent/SA520412278B1/ar unknown
- 2020-07-16 EC ECSENADI202040257A patent/ECSP20040257A/es unknown
- 2020-09-24 US US17/030,603 patent/US11814380B2/en active Active
-
2021
- 2021-04-13 CL CL2021000907A patent/CL2021000907A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200312A (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
| SA518391307B1 (ar) | مركبات ومشتقات سبيرو [ إندول -3، 2- بيروليدين h3] أون جديدة على هيئة مثبطات الدقيقة المزدوجة للفأر(1h)2 بي2-53 | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| MX373033B (es) | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. | |
| MX390347B (es) | Compuestos de aminotiazol como inhibidores de c-kit. | |
| MY196909A (en) | Boronic acid derivatives and therapeutic uses thereof | |
| ECSP18083519A (es) | Inhibidores de bromodominios | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| MX2020001236A (es) | Compuestos aza biciclicos como agonistas del receptor muscarinico m1. | |
| EA201790576A1 (ru) | Спироциклические ингибиторы катепсина с | |
| GEP20227353B (en) | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors | |
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| MX373320B (es) | Compuestos inhibidores de pde2. | |
| CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
| MX2020001531A (es) | Nuevos compuestos hetorociclicos como inhibidores de cdk8/19. | |
| MX382601B (es) | DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß. | |
| MX373162B (es) | Piridopirimidinonas y utilización de las mismas como moduladores de receptores de n-metil-d-aspartato (nmda). | |
| MX386761B (es) | Compuestos de indenilo, composiciones farmacéuticas y usos médicos del mismo. | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| EA201790020A1 (ru) | Соединения, фармацевтические композиции и их применение при лечении нейродегенеративных заболеваний | |
| BR112015023560A8 (pt) | Novos derivados de acrilamida como agentes antimaláricos | |
| MX375329B (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| EA201990074A1 (ru) | Гетероциклические соединения как иммуномодуляторы |